Pamela Stephenson
CIK 1767650 · Chief Commercial Officer · last filed 2026-02-17
Pamela Stephenson is a Chief Commercial Officer who has filed 40 SEC Form 4 insider transactions across 3 companies since 2019. The most recent filing shows the insider sold $347.7K of IRON on Feb 17, 2026. Across all open-market trades the lifetime net is −$805.4K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $6.4M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
IRON price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
80 W. LANCASTER AVENUE, SUITE 300
DEVON, PA 19333
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| IRON | Chief Commercial Officer | 80,998 | $78.93 | $6.39M | -$518.9K | 5 | 2026-02-17 |
| Zynerba Pharmaceuticals, Inc. (ZYNE) Delisted | Director | 47,824 | $1.30 | $62.2K | -$80 | 7 | 2023-10-11 |
| ALBIREO PHARMA, INC. (ALBO) Delisted | Chief Commercial Officer | 0 | $44.15 | $0 | -$286.4K | 27 | 2023-03-02 |
Recent Filings
40 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-02-17 | IRON | Sell (S) | −5,531 | -$347.7K | EDGAR |
| 2026-02-17 | IRON | Notice (144) | −5,531 | -$309.5K | EDGAR |
| 2026-02-11 | IRON | Grant (A) | +17,000 | $0 | EDGAR |
| 2025-02-20 | IRON | Sell (S) | −3,137 | -$171.2K | EDGAR |
| 2025-02-12 | IRON | Grant (A) | +36,000 | $0 | EDGAR |
| 2024-02-27 | IRON | Grant (A) | +36,666 | $0 | EDGAR |
| 2023-10-11 | Zynerba Pharmaceuticals, Inc. (ZYNE) Delisted | Mixed | −75,778 | $0 | EDGAR |
| 2023-06-15 | Zynerba Pharmaceuticals, Inc. (ZYNE) Delisted | Mixed | +47,709 | -$40 | EDGAR |
| 2023-03-02 | ALBIREO PHARMA, INC. (ALBO) Delisted | Mixed | −22,242 | $0 | EDGAR |
| 2023-01-27 | ALBIREO PHARMA, INC. (ALBO) Delisted | Grant (A) | +55,000 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.